The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGlu Rs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.
本发明提供了通式(I)的
吡唑并
喹唑啉酮和
吡咯并
喹唑啉酮衍
生物以及含有它们的药物组合物。此外,式(I)的化合物及其组合物被提供用于治疗和/或预防与谷
氨酸能信号传导和/或功能改变相关的病症,以及可以通过改变哺乳动物中的谷
氨酸
水平或信号传导而受影响的病症。这些通式(I)的
吡唑并
喹唑啉酮和
吡咯并
喹唑啉酮衍
生物可以作为神经系统中对谷
氨酸敏感的受体调节剂,特别是作为代谢型谷
氨酸受体(mGluRs)的调节剂,这使得它们特别适合用于治疗和/或预防急性和慢性神经和/或精神疾病。